Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment.
albumin–bilirubin score
conversion surgery
hepatocellular carcinoma
lenvatinib
sorafenib
tyrosine kinase inhibitor
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
23
01
2022
revised:
25
02
2022
accepted:
14
03
2022
entrez:
23
5
2022
pubmed:
24
5
2022
medline:
24
5
2022
Statut:
epublish
Résumé
Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the candidates eligible for CS because of the higher response rate. The aim of this study was to clarify the characteristics of patients who underwent CS after tyrosine kinase inhibitor (TKI) therapy. In all, 364 patients who were treated with first-line sorafenib (SOR; Six patients underwent CS after TKI therapy, and of these four (1.4%) and two (2.7%) patients received SOR and LEN, respectively. At baseline, patients who underwent CS were significantly younger (median 52 [range, 46-83] years of age, The patients who underwent CS after TKI therapy for HCC experienced long survival, were relatively young, and exhibited radiologic response to TKIs, and their liver function was either maintained or improved. Therefore, CS may lead to a better prognosis in patients with advanced HCC.
Sections du résumé
Background and Aim
UNASSIGNED
Conversion surgery (CS), which aims to cure after systematic therapy, is only scarcely reported in the field of hepatocellular carcinoma (HCC). However, advancements in systemic therapy for HCC are expected to increase the candidates eligible for CS because of the higher response rate. The aim of this study was to clarify the characteristics of patients who underwent CS after tyrosine kinase inhibitor (TKI) therapy.
Methods
UNASSIGNED
In all, 364 patients who were treated with first-line sorafenib (SOR;
Results
UNASSIGNED
Six patients underwent CS after TKI therapy, and of these four (1.4%) and two (2.7%) patients received SOR and LEN, respectively. At baseline, patients who underwent CS were significantly younger (median 52 [range, 46-83] years of age,
Conclusion
UNASSIGNED
The patients who underwent CS after TKI therapy for HCC experienced long survival, were relatively young, and exhibited radiologic response to TKIs, and their liver function was either maintained or improved. Therefore, CS may lead to a better prognosis in patients with advanced HCC.
Identifiants
pubmed: 35601130
doi: 10.1002/jgh3.12735
pii: JGH312735
pmc: PMC9120872
doi:
Types de publication
Journal Article
Langues
eng
Pagination
301-308Informations de copyright
© 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
J Hepatobiliary Pancreat Sci. 2011 Jan;18(1):74-80
pubmed: 20686792
Liver Cancer. 2021 Jul;10(4):320-329
pubmed: 34414120
Ann Oncol. 2005 Aug;16(8):1311-9
pubmed: 15870084
Expert Opin Pharmacother. 2018 Aug;19(11):1167-1170
pubmed: 30011239
Hepatol Res. 2020 Jan;50(1):15-46
pubmed: 31655492
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Hepatol Res. 2020 Jan;50(1):137-143
pubmed: 31349377
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Hepatol Res. 2021 Oct;51(10):1082-1086
pubmed: 33982336
JGH Open. 2020 Oct 16;4(6):1183-1190
pubmed: 33319054
Surg Case Rep. 2020 Dec 10;6(1):318
pubmed: 33301055
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Ann Surg Oncol. 2008 Dec;15(12):3503-11
pubmed: 18777193
Liver Cancer. 2019 Oct;8(5):299-311
pubmed: 31768341
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Invest New Drugs. 2015 Feb;33(1):233-40
pubmed: 25377392
Hepatol Res. 2021 Feb;51(2):201-215
pubmed: 33270323
Medicine (Baltimore). 2020 Oct 16;99(42):e22782
pubmed: 33080748
Liver Cancer. 2019 Mar;8(2):121-129
pubmed: 31019902
Surg Today. 2018 Apr;48(4):431-438
pubmed: 29110089
J Clin Oncol. 2013 Oct 10;31(29):3647-55
pubmed: 24002499
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Front Oncol. 2021 Oct 19;11:747950
pubmed: 34737958
Anticancer Res. 2019 Oct;39(10):5695-5701
pubmed: 31570469
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
Anticancer Res. 2018 Jan;38(1):501-507
pubmed: 29277815
J Hepatol. 2020 Feb;72(2):288-306
pubmed: 31954493
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
Hepatol Res. 2020 Dec;50(12):1375-1385
pubmed: 32924266
Ann Surg Oncol. 2021 Nov;28(12):7663-7672
pubmed: 33904001